Nasdaq · Healthcare

Bionano Genomics, Inc. (BNGO)

As-reported financials and recent SEC filings for Bionano Genomics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$28.5M

Net income

$-26.4M

Net margin

-92.6%

Diluted EPS

$-4.85

ROE

-59.4%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$28.5M	$30.8M	$36.1M	$27.8M	$18.0M
Gross profit	$13.2M	$380,000	$9.6M	$5.9M	$3.9M
Operating income	$-33.3M	$-104.0M	$-215.2M	$-131.7M	$-77.1M
Net income	$-26.4M	$-112.0M	$-232.5M	$-132.6M	$-72.4M
Diluted EPS	$-4.85	$-22.03	$-51.08	$-29.20	$-16.57

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-24

8-K2026-06-05

42026-06-03

42026-06-03

42026-06-03

42026-06-03

8-K2026-05-28

42026-05-14

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on BNGO

Search Bionano Genomics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.